THERAPY DOSSIER · th-6dfcb0ef9318

Progenitor-enriched whole blood or peripheral blood mononuclear cells from donors treated with tocopherol succinate and AMD3100

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24776901 ↗2014Reported benefit

Preclinical development of a bridging therapy for radiation casualties: appropriate for high risk personnel.

MouseRadiationCD2F1MaleIntravenous transfusionAfter irradiation

Model: Acute high-dose whole-body ionising irradiation causing haematopoietic or gastrointestinal acute radiation syndrome

Infusion of whole blood or mononuclear cells from tocopherol succinate and AMD3100-treated donors significantly improved 30-day survival after high-dose irradiation, comparable with cells from granulocyte colony-stimulating factor-treated donors.

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…